5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
PureTech Health's 5-Year ROIIC % for the quarter that ended in Dec. 2025 was 14.73%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for PureTech Health's 5-Year ROIIC % or its related term are showing as below:
PRTCY's 5-Year ROIIC % is ranked better than 69.69% of 1181
companies
in the Biotechnology industry
Industry Median: -11.52
vs PRTCY: 14.73
PureTech Health (OTCPK:PRTCY) 5-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
PureTech Health 5-Year ROIIC % Related Terms
PureTech Health 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for PureTech Health's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRTCY vs VRTX, REGN, ALNY: 5-Year ROIIC % Comparison
For the Biotechnology subindustry, PureTech Health's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PureTech Health 5-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PureTech Health's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where PureTech Health's 5-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
PureTech Health (PRTCY) has a 5-Year ROIIC % of 14.73 as of Dec. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on PureTech Health and its competitors. According to the industry distribution chart, PureTech Health ranks #358 out of 1181 companies in the Biotechnology industry, placing it in the top 30.3%.
Is PureTech Health's 5-Year ROIIC % too high?
PureTech Health's current 5-Year ROIIC % is 14.73. Based on the distribution chart, PureTech Health ranks #358 out of 1181 companies in the Biotechnology industry, which is above the industry midpoint. Overall, PureTech Health has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's 5-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PureTech Health ranks #358 out of 1181 companies for 5-Year ROIIC %. This puts PureTech Health in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Biotechnology company?
A good 5-Year ROIIC % depends on the Biotechnology industry context. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on PureTech Health and its competitors. PureTech Health's current 5-Year ROIIC % is 14.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (PRTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $70.09, compared to a current price of $17.54 — trading 75% below its estimated fair value. The current 5-Year ROIIC % is 14.73. PureTech Health's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For PureTech Health (PRTCY), the current 5-Year ROIIC % is 14.73 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PureTech Health (PRTCY) Overvalued in 2026?
Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued.
The current stock price of $17.54 is trading 75% below its estimated GF Value™ of $70.09.
GuruFocus considers PureTech Health to be Possible Value Trap.
Key valuation signals for PRTCY:
5-Year ROIIC %: 14.73
GF Value™: $70.09 vs. price of $17.54 (75% below fair value)
No single metric tells the full story. See the PRTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
62GF Score
Get the complete analysis for PRTCY
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRTCY has been successfully added to your 
